Jan 09, 2024 / 12:30AM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO as well as Dean Lee, President of Merck Research Labs. So Rob and Dean, Happy New Year. And great speaking of you today. We're going to have a presentation from Rob, and then we're going to move over to a Q&A session from there.
But obviously, it's been quite a year for Merck or quite a few years for Merck. Company's built on its pipeline really nicely. It's been active in a lot of deals. So excited to hear from the progress the company has been making. So with that, turn it over to Rob.
Robert M. Davis - Merck & Co., Inc. - Chairman, President & CEO
Thanks. All right. Great. Happy New Year, everyone. Thanks for having us. Before we get started, I did want to just point out I will be making forward-looking statements, which obviously you can see our statement here and go to our website if you
Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers